Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785218 | 0.93 | GPR119 (0.39) | GPR119F10KDM4DUSP30MCHR1 | |
| SCHEMBL785217 | 0.93 | GPR119 (0.39) | GPR119F10KDM4DUSP30MCHR1 | |
| SCHEMBL803454 | 0.88 | CTSS (0.41) | GPR119F10USP30MCHR1JAK2 | |
| SCHEMBL803651 | 0.84 | GPR119 (0.39) | GPR119F10KDM4DUSP30 | |
| SCHEMBL784857 | 0.84 | CA12 (0.46) | F10MCHR1ROCK2 | |
| SCHEMBL784149 | 0.84 | ROCK2 (0.38) | NPY5RF10MCHR1ROCK2 | |
| SCHEMBL803654 | 0.83 | GPR119 (0.38) | GPR119F10KDM4DUSP30JAK2 | |
| SCHEMBL803496 | 0.83 | GPR119 (0.37) | GPR119NPY5RF10USP30MCHR1 | |
| SCHEMBL803662 | 0.83 | TLR9 (0.39) | GPR119F10USP30JAK2JAK1 | |
| SCHEMBL785013 | 0.83 | ROCK2 (0.39) | F10MCHR1ROCK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | GPR119 698/4885NPY5R 54/4885F10 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.